How do you utilize CDK 4/6 inhibitors in metastatic ER+ HER2+ breast cancer?
One such patient progressed through trastuzumab/pertuzumab/letrozole and TDM1 alone. How would you combine ER+ approaches (eg CDK 4/6 inhibitor + AI) with HER2+ therapy (eg trastuzumab) for the next line of treatment?
Answer from: Medical Oncologist at Academic Institution
The benefit of adding a CDK4/6 inhibitor to the arsenal of treatment options in the hormone receptor (HR) and HER2-positive metastatic breast cancer setting is unknown. We are trying to answer this question through clinical trials, such as the multi-center Randomized, Open Label, Clinical Study of t...
Sign in or Register to read more